Compare FRPH & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRPH | KMDA |
|---|---|---|
| Founded | 1986 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.3M | 458.6M |
| IPO Year | 1995 | 2013 |
| Metric | FRPH | KMDA |
|---|---|---|
| Price | $23.31 | $8.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 41.7K | ★ 65.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.21% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $41,774,000.00 | N/A |
| Revenue This Year | N/A | $14.79 |
| Revenue Next Year | N/A | $11.38 |
| P/E Ratio | $148.00 | ★ $24.59 |
| Revenue Growth | ★ 0.65 | N/A |
| 52 Week Low | $21.68 | $5.54 |
| 52 Week High | $29.86 | $9.35 |
| Indicator | FRPH | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 40.37 | 56.02 |
| Support Level | $23.10 | $6.69 |
| Resistance Level | $24.61 | $9.35 |
| Average True Range (ATR) | 0.50 | 0.27 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 19.27 | 60.00 |
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.